UB-VV100 / Umoja Biopharma - LARVOL DELTA

Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. (PubMed, J Immunother Cancer) - "These findings demonstrate that UB-VV100 generates functional CAR T cells in vivo, which could expand patient access to CAR T technology in both hematological and solid tumors without the need for ex vivo cell manufacturing."

CAR T-Cell Therapy • Journal • Preclinical • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor • CD19 • CD34 • IL15

Umoja Biopharma Announces Participation in Upcoming Scientific Summits (GlobeNewswire) - "Umoja Biopharma, Inc...announced today that the company will participate in two Hanson Wade summits taking place in July in Boston."

Preclinical • Hematological Malignancies • Oncology • Solid Tumor

Preclinical Activity and Safety of UB-VV100, A Novel Lentiviral Vector Product Designed for Selective and Effective In Vivo Engineering of Therapeutic Anti-CD19 CART Cells for B cell Malignancies (ASGCT 2022) - "UB-VV100, a clinical candidate for the treatment of B cell malignancies, contains a payload encoding an anti-CD19 4-1BBz CAR and a novel synthetic receptor, rapamycin-activated cytokine receptor (RACR), designed to drive in vivo CAR T cell survival and persistence without requirements for lymphodepletion through administration of rapamycin. These findings support the potential of the VivoVec platform for generating safe and effective CAR T cells in vivo, which could expand patient access to CAR T technology in both hematologic and solid tumors without the need for ex vivo cell manufacturing or lymphodepletion."

CAR T-Cell Therapy • Preclinical • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor • CD34

Umoja Biopharma Presents New Preclinical Data at ASGCT 2022 Annual Meeting on its VivoVec Platform Describing Preclinical Safety Data for UB-VV100 Product Candidate, VivoVec Engineering for Improved in vivo CAR T cell Generation and Development of a Scalable Manufacturing Platform (GlobeNewswire) - "Umoja’s one oral and two poster presentations demonstrate progress in UB-VV100 IND-enabling studies, manufacturing platform development, and next generation VivoVec surface engineering. Preclinical data provides early evidence of the anti-tumor activity and preliminary preclinical safety of UB-VV100, Umoja’s preclinical candidate for the treatment of B cell malignancies. Preclinical safety studies completed to-date demonstrate the overall low risk for off target transduction after in vivo administration of UB-VV100 in two animal models, including a model of intranodal delivery. Additional development of next generation VivoVec particle surface engineering with costimulatory ligands to promote T cell binding, activation, and transduction by replicating immune synapse formation will enable efficient in vivo CAR T cell generation and subsequent anti-tumor immune activity. "

Preclinical • Hematological Malignancies • Oncology